Drug Discovery Services Market: Global Growth, Trends, Opportunities, and Industry Outlook
The Drug Discovery Services Market is expanding as pharmaceutical and biotechnology companies increasingly outsource research activities to specialized contract research organizations (CROs). The market was estimated at USD 115.08 billion in 2025 and is projected to reach USD 216.04 billion by 2035, growing at a CAGR of 6.50%.
Growing drug-development costs, complex research requirements, and the need to accelerate candidate identification are encouraging companies to rely on external discovery specialists. CROs provide services across target identification, hit generation, screening, lead optimization, ADME/DMPK studies, and preclinical candidate selection.
Artificial intelligence and machine learning are becoming important market drivers. AI-based platforms can support target validation, virtual screening, molecular design, and predictive analysis, helping researchers shorten discovery timelines. According to Market Research Future, AI and machine-learning platforms are projected to grow at a 10.30% CAGR through 2035.
Small molecules currently represent the largest drug-type segment, while biologics and large-molecule programs are expanding rapidly. Oncology remains a leading therapeutic area because of extensive research into immuno-oncology, targeted therapies, and antibody-drug conjugates.
North America currently leads the market, while Asia-Pacific is projected to be the fastest-growing region. Increasing CRO capacity, biotechnology investment, and research infrastructure in China and India are creating significant opportunities. Overall, AI adoption, outsourcing, advanced screening technologies, and growing pharmaceutical pipelines are expected to support sustained market expansion.